

Prescribe. Play. Progress.

Interested in a non-drug ADHD treatment?

It's actually a video game for inattention!

What is EndeavorRx®?

- EndeavorRx is the first FDA-authorized treatment for primarily inattentive or combined-type ADHD delivered through a video game, and is proven to improve attention in children 8-12 years old.^{1,2}
- EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of ADHD¹

Answer these questions to see if your child may benefit from EndeavorRx

Is your child between 8 and 12 years of age?

Yes No

Has your child been diagnosed with inattentive or combined-type ADHD?

Yes No

Are you interested in a treatment that can be added on to any therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, and may help improve your child's ability to pay attention and stay focused?

Yes No

If you answered "Yes" to the questions above, ask your doctor about EndeavorRx.

How effective is EndeavorRx?

- EndeavorRx is designed to directly target key areas of the brain that play a role in attention function, as opposed to simply managing symptoms
 - In clinical studies using EndeavorRx:
 - 73%** of children reported an improvement in their attention³
 - 68%** of parents reported improvements in ADHD-related impairments after 2 months of treatment⁴
 - 0%** There were no serious adverse events seen in any clinical trials of EndeavorRx^{3,4}
 - The game's technology adjusts as the child plays, adapting the difficulty level in real time to continuously challenge each child

If your child is struggling with attention and focus, ask your child's doctor about EndeavorRx.

Please see EndeavorRx Indications, Safety, and Cautions on the reverse side.

 EndeavorRx
By ANILI®

EndeavorRx: Indications, Safety, and Cautions

Indications for Use:

EndeavorRx is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

Safety:

Of 538 participants using EndeavorRx, 50 participants (9.3%) experienced treatment-related adverse events (probable, likely), and three participants experienced treatment-related adverse events with the digital control, in studies where a control was used. EndeavorRx associated adverse events included frustration (6.1%), headache (1.3%), dizziness (0.6%), emotional reaction (0.4%), nausea (0.4%), and aggression (0.2%). There were no serious adverse events. All adverse events were generally transient. Only 3 events led to device discontinuation, and no subject reported lasting or irreversible effects after discontinuation.

Cautions:

Rx only: Federal law restricts this device to sale by or on the order of a physician. EndeavorRx should only be used by the patient for whom the prescription was written. For medical questions, please contact your child's healthcare provider. If you are experiencing a medical emergency, please dial 911. EndeavorRx is not intended to be used as a stand-alone therapeutic and is not a substitution for your child's medication.

If your child experiences frustration, emotional reaction, dizziness, nausea, headache, eye-strain, or joint pain while playing EndeavorRx pause the treatment. If the problem persists contact your child's healthcare provider. If your child experiences a seizure stop the treatment and contact your child's healthcare provider.

EndeavorRx may not be appropriate for patients with photo-sensitive epilepsy, color blindness, or physical limitations that restrict use of a mobile device; parents should consult with their child's healthcare provider.

Please follow all of your mobile device manufacturer's instructions for the safe operation of your mobile device. For example, this may include appropriate volume settings, proper battery charging, not operating the device if damaged, and proper device disposal. Contact your mobile device manufacturer for any questions or concerns that pertain to your device.

- References:** **1.** EndeavorRx Instructions for Use, v2.5. Akili Interactive Labs, Inc. 2021-2022. **2.** FDA press release; June 15, 2020. Accessed June 3, 2022. <https://www.fda.gov/news-events/news-announcements/fda-permits-marketing-first-game-based-digitaltherapeutic-improve-attention-function-children-adhd> **3.** Kollins SH, et al. *Lancet Digit Health*. 2020;2(4):e168-e178. **4.** Kollins SH, et al. *NPJ Digit Med*. 2021;4(1):58.

